Effects of Black Soy Peptide Supplementation on Blood Pressure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Black soy peptides have been shown to possess properties that may decrease blood pressure. To examine the effects of black soy peptides supplementation on blood pressure and oxidative stress in subjects with pre-hypertension or stage I hypertension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial of Protein and Blood Pressure

NCT00107744

Hypertension Hypercholesterolemia

COMPLETED NA

Soy Peptide, Conjugated Linoleic Acid, Overweight or Obese, Body Composition

NCT04728399

Overweight or Obesity

UNKNOWN NA

Effect of Whey Protein on Blood Pressure

NCT00659672

High Blood Pressure

COMPLETED NA

Clinical Trial of Dietary Protein and Blood Pressure

NCT00046566

Cardiovascular Diseases Hypertension Heart Diseases

COMPLETED NA

Effects of Protein Supplementation on 4 Weeks of Alternate-day Fasting on Fasting Blood Glucose, Resting Blood Pressure, and Body Composition in Young Men

NCT07241689

Obesity & Overweight

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Trial participants included men and women aged 30 to 65 years who had an average systolic blood pressure (SBP) between 130 to 159 mmHg, average diastolic blood pressure (DBP) between 80 to 99 mmHg, or both, based on an average of six measurements during two screening visits. Participants were supplied with 84 pouches of placebo (casein) or black soy peptide (3 pouches/day) at 0-week and at 4-week visits. Test group subjects received pouches containing black soy peptides (4.5 g/day total soy peptides for 8 weeks). The control group received pouches containing casein that had a similar appearance to the black soy peptide tablet. During the intervention, we instructed study participants to continue their current food intake patterns and lifestyles so that total energy intake and energy expenditure would be constant during the course of trial. Participants brought back unconsumed pouches at their 4- and 8-week follow-up visits. The dietitian counted the number of returned pouches, and we used this to assess the participants' adherence to their assigned intervention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

4.5g/day black soy peptide

4.5 g/day, 8weeks

Group Type EXPERIMENTAL

black soy peptide

Intervention Type DIETARY_SUPPLEMENT

black soy peptide: 4.5g/day for 8 weeks

placebo

similar appearance to the black soy peptide tablet, 8 weeks

Group Type PLACEBO_COMPARATOR

black soy peptide

Intervention Type DIETARY_SUPPLEMENT

black soy peptide: 4.5g/day for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

black soy peptide

black soy peptide: 4.5g/day for 8 weeks

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Average systolic blood pressure (SBP) between 130 to 159 mmHg
* Average diastolic blood pressure (DBP) between 80 to 99 mmHg, or both, based on an average of six measurements during two screening visits

Exclusion Criteria

* Previous diagnosed clinical hypertension
* Self-reported use of anti-hypertensive medication
* Abnormal liver or renal function
* History of cardiovascular disease, cancer, thyroid or pituitary disease, or any other serious life-threatening illness that required regular medical treatment

Minimum Eligible Age

30 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No